Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Two Capecitabine + Docetaxel Regimens in Advanced/Metastatic Breast Cancer
2005-004976-18Phase 2Completed
- Sponsor
- Roche
- Start
- May 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capecitabine and docetaxel in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Time to tumor progression or death (TTP). Started May 2006; status: completed.
02
Drugs
capecitabinedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-004976-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004976-18.